John Libbey Eurotext

European Journal of Dermatology

Expert opinion: defining response to omalizumab in patients with chronic spontaneous urticaria Volume 27, numéro 5, September-October 2017

  • [1] Zuberbier T., Aberer W., Asero R. The EAACI/GALEN/EDF/WAO Guideline for the definition, classification, diagnosis and management of urticaria. The 2013 revision and update. Allergy. 2014;69:868-887. 2
  • [2] Maurer M., Weller K., Bindslev-Jensen C. Unmet clinical needs in chronic spontaneous urticaria. A GALEN task force report. Allergy. 2011;66:317-330. 2
  • [3] O’Donnell B.F. Urticaria: impact on quality of life and economic cost. Immunol Allergy Clin North Am. 2014;34:89-104.
  • [4] Staubach P., Dechene M., Metz M. High prevalence of mental disorders and emotional distress in patients with chronic spontaneous urticaria. Acta Derm Venereol. 2011;91:557-561.
  • [5] Delong L.K., Culler S.D., Saini S.S., Beck L.A., Chen S.C. Annual direct and indirect health care costs of chronic idiopathic urticaria: a cost analysis of 50 nonimmunosuppressed patients. Arch Dermatol. 2008;144:35-39.
  • [6] Asero R. Chronic unremitting urticaria: is the use of antihistamines above the licensed dose effective? A preliminary study of cetirizine at licensed and above-licensed doses. Clin Exp Dermatol. 2007;32:34-38.
  • [7] Staevska M., Popov T.A., Kralimarkova T. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol. 2010;125:676-682.
  • [8] Sharma M., Bennett C., Carter B., Cohen S.N. H1-antihistamines for chronic spontaneous urticaria: an abridged Cochrane Systematic Review. J Am Acad Dermatol. 2015;73:710-716.
  • [9] Kameyoshi Y., Tanaka T., Mihara S., Takahagi S., Niimi N., Hide M. Increasing the dose of cetirizine may lead to better control of chronic idiopathic urticaria: an open study of 21 patients. Br J Dermatol. 2007;157:803-804.
  • [10] Ferrer M., Sastre J., Jauregui I. Effect of antihistamine up-dosing in chronic urticaria. J Investig Allergol Clin Immunol. 2011;21:34-39.
  • [11] Sánchez-Borges M., Ansotegui I., Jimenez J.M., Rojo M.I., Serrano C., Yanez A. Comparative efficacy of non-sedating antihistamine updosing in patients with chronic urticaria. World Allergy Organ J. 2014;7:33.
  • [12] Guillén-Aguinaga S., Jáuregui Presa I., Aguinaga-Ontoso E., Guillen-Grima F., Ferrer M. Updosing non-sedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis. Br J Dermatol. 2016;175:1153-1165.
  • [13] US Food and Drug Administration. Omalizumab (marketed as Xolair) Information 2014. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm103291.htm. Last accessed: 27 April 2017.
  • [14] European Medicines Evaluation Agency (EMEA). Omalizumab (Xolair). Summary of Product Characteristics (SmPC) 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000606/WC500057298.pdf. Last accessed: 27 April 2017.
  • [15] Labrador-Horrillo M., Ferrer M. Profile of omalizumab in the treatment of chronic spontaneous urticaria. Drug Des Devel Ther. 2015;9:4909-4915.
  • [16] Eggel A., Baravalle G., Hobi G. Accelerated dissociation of IgE-FcepsilonRI complexes by disruptive inhibitors actively desensitizes allergic effector cells. J Allergy Clin Immunol. 2014;133:1709-1719.
  • [17] Serrano-Candelas E., Martinez-Aranguren R. Comparable actions of omalizumab on mast cells and basophils. Clin Exp Allergy. 2016;46:92-102.
  • [18] Kaplan A., Ledford D., Ashby M. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132:101-109.
  • [19] Saini S.S., Bindslev-Jensen C., Maurer M. Efficacy and safety of omalizumab in patients with chronic idiopathic urticaria/chronic spontaneous urticaria who remain symptomatic on H-antihistamines: a randomized placebo-controlled study. J Invest Dermatol. 2015;135:67-75. 1
  • [20] Maurer M., Rosén K., Hsieh H.J. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368:924-935.
  • [21] Fiorino I., Loconte F., Rucco A.S. Long-term treatment of refractory severe chronic urticaria by omalizumab: analysis of two cases. Postepy Dermatol Alergol. 2014;31:332-334.
  • [22] Silva P.M., Costa A.C., Mendes A., Barbosa M.P. Long-term efficacy of omalizumab in seven patients with treatment-resistant chronic spontaneous urticaria. Allergol Immunopathol. 2015;43:168-173.
  • [23] Uysal P., Eller E., Mortz C.G., Bindslev-Jensen C. An algorithm for treating chronic urticaria with omalizumab: dose interval should be individualized. J Allergy Clin Immunol. 2014;133:914-915.
  • [24] Młynek A., Zalewska-Janowska A., Martus P., Staubach P., Zuberbier T., Maurer M. How to assess disease activity in patients with chronic urticaria? Allergy. 2008;63:777-780.
  • [25] Maurer M., Altrichter S., Bieber T. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol. 2011;128:202-209.
  • [26] Saini S., Rosén K.E., Hsieh H.J. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011;128:567-573.
  • [27] Saini S.S., Bindslev-Jensen C., Maurer M. Efficacy and safety of omalizumab in H-antihistamine-refractory chronic idiopathic/spontaneous urticaria: results of a Phase III randomized, double-blind, placebo-controlled trial. Ann Allergy Asthma Immunol. 2013;111:A18. 1
  • [28] Metz M., Ohanyan T., Church M.K., Maurer M. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. J Dermatol Sci. 2014;73:57-62.
  • [29] Rottem M., Segal R., Kivity S. Omalizumab therapy for chronic spontaneous urticaria: the Israeli experience. Isr Med Assoc J. 2014;16:487-490.
  • [30] Sussman G., Hébert J., Barron C. Real-life experiences with omalizumab for the treatment of chronic urticaria. Ann Allergy Asthma Immunol. 2014;112:170-174.
  • [31] Labrador-Horrillo M., Valero A., Velasco M. Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in real-life practice. Expert Opin Biol Ther. 2013;13:1225-1228.
  • [32] Casale T.B., Bernstein J.A., Maurer M. Similar efficacy with omalizumab in chronic idiopathic/spontaneous urticaria despite different background therapy. J Allergy Clin Immunol Pract. 2015;3:743-750.
  • [33] Kaplan A., Ferrer M., Bernstein J.A. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. J Allergy Clin Immunol. 2016;137:474-481.
  • [34] Giménez-Arnau A.M., Grattan C., Zuberbier T., Toubi E. An individualized diagnostic approach based on guidelines for chronic urticaria (CU). J Eur Acad Dermatol Venereol. 2015;29:3-11.
  • [35] Stull D.E., McBride D.W., Giménez-Arnau A., Grattan C., Khalil S., Balp M.-M. Validation of chronic spontaneous/idiopathic urticaria (CSU/CIU) health states using weekly urticaria activity score (UAS7) and Dermatology Life Quality Index (DLQI). J Am Acad Dermatol. 2015;72:AB154.
  • [36] Weller K, Grattan C, Abuzakouk M, et al. Patient profile from the first international burden of illness study in inadequately controlled chronic spontaneous urticaria: ASSURE-CSU. Presented at the Annual Congress of the European Academy of Dermatology and Venereology (EADV), Copenhagen, Denmark, 7-10 October 2015.(Latebreaker ePoster LATCOP-0036).
  • [37] Maurer M, Spector S, Bernstein JA, et al. Effect of omalizumab over a 6-month treatment period on angioedema and quality of life associated with refractory chronic idiopathic/spontaneous urticaria (CIU/CSU): subgroup analyses focused on the presence of baseline angioedema. Presented at the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI), Barcelona, Spain, 6-10 June 2015.(Poster TPS-51).
  • [38] Kang M.J., Kim H.S., Kim H.O., Park Y.M. The impact of chronic idiopathic urticaria on quality of life in Korean patients. Ann Dermatol. 2009;21:226-229.
  • [39] Silvares M.R., Fortes M.R., Miot H.A. Quality of life in chronic urticaria: a survey at a public university outpatient clinic, Botucatu (Brazil). Rev Assoc Med Bras. 2011;57:577-582.
  • [40] Staubach P., Metz M., Rothe-Chapman N. Effect of omalizumab on angioedema in H1-antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial. Allergy. 2016;71:1135-1144.
  • [41] Weller K., Groffik A., Church M.K. Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol. 2014;133:1365-1372.
  • [42] Weller K., Zuberbier T., Maurer M. Chronic urticaria: tools to aid the diagnosis and assessment of disease status in daily practice. J Eur Acad Dermatol Venereol. 2015;29:38-44.
  • [43] Finlay A.Y., Khan G.K. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210-216.
  • [44] Lennox R.D., Leahy M.J. Validation of the Dermatology Life Quality Index as an outcome measure for urticaria-related quality of life. Ann Allergy Asthma Immunol. 2004;93:142-146.
  • [45] Cardiff University. Dermatology Life Quality Index (DLQI). 1992. Available at: http://sites.cardiff.ac.uk/dermatology/quality-of-life/dermatology-quality-of-life-index-dlqi. Last accessed: 27 April 2015.
  • [46] Baiardini I., Pasquali M., Braido F. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL). Allergy. 2005;60:1073-1078.
  • [47] Ghazanfar M., Sand C., Thomsen S.F. Effectiveness and safety of omalizumab in chronic spontaneous or inducible urticaria: evaluation of 154 patients. Br J Dermatol. 2016;175:404-406.
  • [48] Weller K., Groffik A., Magerl M. Development, validation, and initial results of the Angioedema Activity Score. Allergy. 2013;68:1185-1192.
  • [49] Palacios T., Stillman L., Borish L., Lawrence M. Lack of basophil CD203c-upregulating activity as an immunological marker to predict response to treatment with omalizumab in patients with symptomatic chronic urticaria. J Allergy Clin Immunol Pract. 2016;4:529-530.
  • [50] Gericke J., Metz M., Ohanyan T. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. J Allergy Clin Immunol. 2016;139:1059-1061.
  • [51] Metz M., Ohanyan T., Church M.K., Maurer M. Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria. JAMA Dermatol. 2014;150:288-290.
  • [52] Clinicaltrials.gov. OPTIMA: Efficacy of optimized re-treatment and step-up therapy with omalizumab in chronic spontaneous urticaria (CSU) patients. Available at: https://clinicaltrials.gov/ct2/show/NCT02161562. Last accessed: 27 April 2017.